国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
2期
276-278
,共3页
上皮型单纯疱疹病毒性角膜炎%更昔洛韦眼用凝胶%重组人干扰素α-2b滴眼液
上皮型單純皰疹病毒性角膜炎%更昔洛韋眼用凝膠%重組人榦擾素α-2b滴眼液
상피형단순포진병독성각막염%경석락위안용응효%중조인간우소α-2b적안액
epithelial herpes simplex viral keratitis%ganciclovir ophthalmic gel%recombinant human interferonα-2b eye drops
目的：观察重组人干扰素α-2b滴眼液联合更昔洛韦眼用凝胶治疗上皮型单纯疱疹病毒性角膜炎（ HSK）的疗效。<br> 方法：选取2011-04/2012-10在荆门市中医医院眼科门诊确诊的50例50眼上皮型HSK患者，将其随机分为对照组和试验组两组。两组均予以1．5g/L更昔洛韦眼用凝胶滴眼，每日6次；试验组在此基础予以重组人干扰素α-2 b滴眼液滴眼，每日6次，用药疗程均为4 wk。比较两组患者临床治愈率，角膜溃疡愈合时间，疼痛减轻时间以及视力改善情况等。<br> 结果：两组患者治疗前的一般情况无显著差异（ P＞0．05）。试验组临床治愈率为69％；对照组患者临床治愈率为42％；试验组患者临床治愈率明显高于对照组，组间比较差异有统计学意义（P＜0．05）；试验组患者角膜溃疡愈合及疼痛减轻时间均明显优于对照（P＜0．05）。<br> 结论：重组人干扰素α-2b滴眼液联合更昔洛韦眼用凝胶治疗上皮型HSK疗效确切，能明显提高视力、临床治愈率，缩短病程，是目前治疗上皮型HSK较理想的方法。
目的：觀察重組人榦擾素α-2b滴眼液聯閤更昔洛韋眼用凝膠治療上皮型單純皰疹病毒性角膜炎（ HSK）的療效。<br> 方法：選取2011-04/2012-10在荊門市中醫醫院眼科門診確診的50例50眼上皮型HSK患者，將其隨機分為對照組和試驗組兩組。兩組均予以1．5g/L更昔洛韋眼用凝膠滴眼，每日6次；試驗組在此基礎予以重組人榦擾素α-2 b滴眼液滴眼，每日6次，用藥療程均為4 wk。比較兩組患者臨床治愈率，角膜潰瘍愈閤時間，疼痛減輕時間以及視力改善情況等。<br> 結果：兩組患者治療前的一般情況無顯著差異（ P＞0．05）。試驗組臨床治愈率為69％；對照組患者臨床治愈率為42％；試驗組患者臨床治愈率明顯高于對照組，組間比較差異有統計學意義（P＜0．05）；試驗組患者角膜潰瘍愈閤及疼痛減輕時間均明顯優于對照（P＜0．05）。<br> 結論：重組人榦擾素α-2b滴眼液聯閤更昔洛韋眼用凝膠治療上皮型HSK療效確切，能明顯提高視力、臨床治愈率，縮短病程，是目前治療上皮型HSK較理想的方法。
목적：관찰중조인간우소α-2b적안액연합경석락위안용응효치료상피형단순포진병독성각막염（ HSK）적료효。<br> 방법：선취2011-04/2012-10재형문시중의의원안과문진학진적50례50안상피형HSK환자，장기수궤분위대조조화시험조량조。량조균여이1．5g/L경석락위안용응효적안，매일6차；시험조재차기출여이중조인간우소α-2 b적안액적안，매일6차，용약료정균위4 wk。비교량조환자림상치유솔，각막궤양유합시간，동통감경시간이급시력개선정황등。<br> 결과：량조환자치료전적일반정황무현저차이（ P＞0．05）。시험조림상치유솔위69％；대조조환자림상치유솔위42％；시험조환자림상치유솔명현고우대조조，조간비교차이유통계학의의（P＜0．05）；시험조환자각막궤양유합급동통감경시간균명현우우대조（P＜0．05）。<br> 결론：중조인간우소α-2b적안액연합경석락위안용응효치료상피형HSK료효학절，능명현제고시력、림상치유솔，축단병정，시목전치료상피형HSK교이상적방법。
AIM:To study the clinical effects of recombinant human interferonα-2b eye drops combined with ganciclovir ophthalmic gel on the treatment of epithelial herpes simplex viral keratitis ( HSK) . <br> METHODS: Totally 50 cases ( 50 eyes ) with epithelial HSK diagnosed in Ophthalmology Department of Jingmen Traditional Chinese Medicine Hospital from April 2011 to October 2012 were enrolled.All the patients were divided into control group and experimental group randomly. Control group was treated by 1.5g/L ganciclovir ophthalmic gel, 6 times per day, while experimental group was treated by 1.5g/L ganciclovir ophthalmic gel combined with recombinant human interferon α-2b eye drops, 6 times per day.All patients were treated for 4 weeks. Then the therapeutic effects of two groups, including the cure rate, time of corneal ulcer healing, pain relief and vision improvement, were compared and analyzed. <br> RESULTS: No significant differences in general condition between two groups was detected before treatment ( P >0.05 ). The therapeutic effects of experimental group was better than the control group. The cure rate was 69% for experimental group and 42%for control group.The clinical cure rate in experimental group was significantly higher than that of the control group, there was statistically significant difference between the two groups ( P<0.05).The time for corneal ulcer healing and pain relief in experimental group was significantly shorter than that for the control group ( P<0.05 ) . <br> CONCLUSION:The application ofganciclovir ophthalmic gel combined with recombinant human interferon α-2b eye drops in epithelial herpes simplex viral keratitis, which improves visual acuity and the cure rate and shortens the course of disease, is the ideal treatment of epithelial herpes simplex viral keratitis at present.
